Navigation Links
Anadys Pharmaceuticals to Present at the Roth OC Growth Stock Conference
Date:2/9/2009

SAN DIEGO, Feb. 9 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the 21st Annual Roth OC Growth Stock Conference on Monday, February 16, 2009 at 1:00 p.m. PST (4:00 p.m. EST). The conference is being held at The Ritz-Carlton, Laguna Niguel.

Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will provide an overview of Anadys and its clinical programs: ANA598 and ANA773 in hepatitis C and ANA773 in cancer.

The presentation will be simultaneously webcast and can be accessed on the Investor Relations page of the Company's website at www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through March 2, 2009.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medicines in the areas of hepat
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology news :

1. Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design
2. NMR researchers unlock hydrogens secrets to spot polymorphism in pharmaceuticals
3. Researchers develop liquid crystal pharmaceuticals to fight cancer and other diseases
4. Bacteria from sponges make new pharmaceuticals
5. Hypertension and cholesterol medications present in water released into the St. Lawrence River
6. Sea bed provides information about present climatic change
7. David Rose to present Howe School lecture on new technologies and business models, Jan. 29
8. New manual presents robust, state-of-the-art proteomics methods for teaching and research
9. Hobbit fossils represent a new species, concludes University of Minnesota anthropologist
10. UAF researchers to present at AGU press briefing
11. New gene variants present opportunities in nutrigenomics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... University researchers have developed a suite of technologies that ... humans, which has applications in everything from search and ... "We,ve developed a platform for computer-mediated communication between humans ... for interpreting dogs, behavioral signals and sending them clear ... an assistant professor of computer science at NC State ...
(Date:10/29/2014)... who lose their hair as a consequence of chemotherapy ... improve the scalp cooling technology that prevents hair loss. ... being pioneered by global scalp cooling manufacturing company, Paxman ... biology department of the University of Huddersfield. , The ... who has a background in the pharmacology of cancer ...
(Date:10/29/2014)... factors, both genetic and environmental, have been blamed ... schizophrenia. Some, such as a family history of ... with Toxoplasma gondii , a parasite transmitted ... still viewed with skepticism. , A new study ... epidemiology at the University of Pennsylvania,s School of ...
Breaking Biology News(10 mins):New tech aims to improve communication between dogs and humans 2New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2Penn vet professor investigates parasite-schizophrenia connection 2Penn vet professor investigates parasite-schizophrenia connection 3
... have found that a strain of tuberculosis (TB) responsible ... first introduced to these communities by French Canadian fur ... found a traceable link between the fur trade routes ... professor with Queen,s Division of Infectious Diseases, is the ...
... Melding nanotechnology and medical research, Sandia National Laboratories, the ... and Treatment Center have produced an effective strategy that ... of killer drugs. , In the cover article of ... online April 17 , the researchers describe silica nanoparticles ...
... Monday, April 18, 2011, Cleveland: Researchers have identified ... as the cause of a fatal developmental disease in ... April 8, 2011, issue of Science . ... the cellular protein-making process, causing microcephalic osteodysplastic primoridal dwarfism ...
Cached Biology News:Tuberculosis strain in indigenous communities linked to Canadian fur trade 2Sandia and UNM lead effort to destroy cancers 2Sandia and UNM lead effort to destroy cancers 3Genetic mutation linked to lethal disease 2
(Date:10/30/2014)... James Sherley says he has been working ... cell technology since his days as a principal investigator at ... late 1990’s. Sherley founded the ASCTC as a new ... the intellectual property developed in Sherley’s research over the years ... of Technology (MIT), and more recently as a senior scientist ...
(Date:10/30/2014)... 30, 2014 Grace Century portfolio project, ... Manganello, Chairman of the Board, to the National Stem ... appointment was made by the Ministry of Health on behalf ... , More than a year after Bahamian Parliament ... Prime Minister Perry Christie said the government has completed the ...
(Date:10/30/2014)... of the key challenges in the development of quantum ... , In a paper published today (28 October) in ... show how to make a new type of flexibly ... such as high-precision sensors and specialised superfast computers, often ... the methods for trapping these tiny particles are hugely ...
(Date:10/27/2014)... , October 27, 2014 ... right to produce, exhibit and sell its artificial ... to impeach their patent.      (Photo: ... four years of fighting, the definitive judgement has ... and produces innovative and accessible hi-tech prostheses with ...
Breaking Biology Technology:Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2
... NeuroCog Trials, Inc. today announced the appointment of Michael ... Officer.  In this newly created position, Dr. Hufford will ... NeuroCog Trials, business, research and development, and operations. ... therapies across a wide variety of therapeutic areas has ...
... November 4, 2011 Major milestone achieved ... treatment of patients with refractory ascites due to liver ... Vienna and Vienna General Hospital (AKH Wien) reported that ... System were performed at Vienna General Hospital in October, ...
... Nov. 3, 2011 Sequenom, Inc. (NASDAQ: SQNM ), ... total revenues of $13.6 million for the third quarter of 2011, ... the third quarter of 2010.  Net loss for the third quarter ... to net loss of $22.7 million, or $0.30 per share for ...
Cached Biology Technology:NeuroCog Trials Appoints Industry Executive Michael Hufford, Ph.D. to Chief Operating Officer 2The Medical University of Vienna and Vienna General Hospital Perform the First two Commercial Implants Worldwide of Sequana Medical's ALFApump® System 2Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011 2Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011 3Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011 4Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011 5Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011 6Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011 7Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011 8
Chicken Anti-Human Stomatin-like 2 (STOML2 Polyclonal AntibodyNew Applications: ELISA, Western Blot...
Anti-Chicken IgY, (IgG) F(ab')2 Fragment Specific....
... (Ankyrin repeat and SOCS box-containing protein) This ... containing amino acids 75-93 and 348-368 of ... Catalog No. 40149) can be used as ... with mouse and rat Asb-2, based on ...
Monoclonal Anti-Gα o purified immunoglobulin buffered aqueous solution Solution in phosphate buffered saline pH 7.4, containing 0.08% sodium azide. partially purified bovine brain Gα O ...
Biology Products: